NCI long-term study a positive result for BiovaxID
22:03 EDT 7 Jun 2012 | Florida Biotech News
Phase II BiovaxID® lymphoma vaccine clinical trial results, presented by the NCI, demonstrated that vaccination following rituximab combination chemotherapy induced nearly universal T-cell immune responses, the elevation of which strongly correlated..
Original Article: NCI long-term study a positive result for BiovaxID
More From BioPortfolio on "NCI long-term study a positive result for BiovaxID"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
